Please login to the form below

Not currently logged in
Email:
Password:

MK-1775

This page shows the latest MK-1775 news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio

AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio

These include licensing the WEE1 inhibitor MK-1775 from Merck &Co, the $500m buyout of biotech Amplimmune and its portfolio of cancer antibodies, an alliance with the UK biotech Immunocore via

Latest news

  • AZ licenses Merck ovarian cancer drug AZ licenses Merck ovarian cancer drug

    The deal gives AZ worldwide rights to MK-1775, an oral, small-molecule inhibitor of WEE1 kinase that is being tested initially in ovarian cancer patients with mutations in the p53 ... AZ will be responsible for all future clinical development,

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    Fostering partnerships. Recent developments include agreements to license the WEE1 inhibitor MK-1775 from Merck &Co and a collaboration with Bind Therapeutics which puts a molecule discovered by AZ – an Aurora

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    Licence. Diagnostic products IVD. 75. Merck &Co / AstraZeneca. Licence. WEE1 kinase (MK-1775) for ovarian cancer.

  • Pharma deals during September 2013 Pharma deals during September 2013

    Another oncology deal of note was AstraZeneca's(AZ) licence of Merck &Co's WEE1 kinase (MK-1775) currently being evaluated in phase IIa clinical studies in combination with standard of ... death. Preclinical evidence suggests that the combination of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics